News
ICPT
18.40
+0.16%
0.03
B.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)
TipRanks · 2d ago
Intercept Pharma gains after patent settlement with Amneal
Seeking Alpha · 2d ago
AT&T, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
Benzinga · 2d ago
BRIEF-Intercept Pharmaceuticals- On Jan 24, Co, Unit Entered Into Settlement Agreement With Amneal EU, Limited, Amneal Pharmaceuticals Of New York, Llc
Reuters · 2d ago
Intercept: Huge Potential Upsides With Binary Catalyst Unlocking
Seeking Alpha · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intercept Pharma (ICPT), Synlogic (SYBX) and Editas Medicine (EDIT)
TipRanks · 4d ago
UBS Adjusts Price Target on Intercept Pharmaceuticals to $20 From $23, Maintains Neutral Rating
UBS Adjusts Price Target on Intercept Pharmaceuticals to $20 From $23, Maintains Neutral Rating
MT Newswires · 5d ago
Intercept Pharma (ICPT) Receives a Buy from Robert W. Baird
TipRanks · 5d ago
Intercept: FDA Accepts Application For Ocaliva In NASH
Seeking Alpha · 01/20 21:08
Raymond James Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $26
Benzinga · 01/20 09:37
Raymond James Trims Price Target on Intercept Pharmaceuticals to $26 From $27, Maintains Outperform Rating
Raymond James Trims Price Target on Intercept Pharmaceuticals to $26 From $27, Maintains Outperform Rating
MT Newswires · 01/20 09:30
Needham Sticks to Their Buy Rating for Intercept Pharma (ICPT)
TipRanks · 01/19 15:35
JMP Securities Keeps Their Hold Rating on Intercept Pharma (ICPT)
TipRanks · 01/19 15:15
Intercept gains as NASH candidate goes under FDA review
Seeking Alpha · 01/19 14:02
Intercept Pharmaceuticals Announces FDA Accepts The Co.'s New Drug Application For OCA For The Treatment Of Pre-Cirrhotic Liver Fibrosis Due To NASH
Benzinga · 01/19 13:15
BRIEF-FDA Accepts Intercept's New Drug Application For Oca For The Treatment Of Pre-Cirrhotic Liver Fibrosis Due To Nash
Reuters · 01/19 13:08
Intercept Pharmaceuticals New Drug Application for NASH Treatment Accepted by FDA; Shares Rise
Intercept Pharmaceuticals New Drug Application for NASH Treatment Accepted by FDA; Shares Rise
MT Newswires · 01/19 08:43
BRIEF-Intercept, Unit Enters Into Agreement With Optimus Pharma, Optimus Drugs
Reuters · 01/17 15:20
On Jan 14, Intercept Pharmaceuticals And Unit Entered Into A Settlement Agreement With Optimus Pharma Pvt. And Optimus Drugs Pvt.; Granted Optimus Non-exclusive, Royalty-Free License To Commercialize Generic Version Of Ocaliva In U.S. From April 26, 2034
Benzinga · 01/17 13:09
RBC Capital Reaffirms Their Hold Rating on Intercept Pharma (ICPT)
TipRanks · 01/17 01:46
More
Webull provides a variety of real-time ICPT stock news. You can receive the latest news about Intercept Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. The Company’s other compounds are in early stages of research and development pipeline, including INT-787 compound, an FXR agonist is in a Phase I clinical trial.